Literature DB >> 2105150

Absorption of intranasal salmon calcitonin in normal subjects and hypogonadic men.

K K Pun1, L W Chan, P Lau, P W Ho, C Wang.   

Abstract

The absorption kinetics of intranasal salmon calcitonin were assessed in 4 normal subjects and 9 patients with Klinefelter's syndrome. After administration, absorption occurred within 5 minutes. There was a highly significant correlation between the amount administered and the amount absorbed (r = -0.83, P less than 0.0005).

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2105150     DOI： 10.1007/bf02556097

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


  6 in total

1.  Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.

Authors:  G F Mazzuoli; M Passeri; C Gennari; S Minisola; R Antonelli; C Valtorta; E Palummeri; G F Cervellin; S Gonnelli; G Francini
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

Review 2.  Male hypogonadism: risks for myocardial infarction and bone fracture.

Authors:  C M Swartz; M A Young
Journal:  Compr Ther       Date:  1988-04

3.  Intranasal absorption of salmon calcitonin.

Authors:  H Kurose; Y Seino; M Shima; H Tanaka; M Ishida; K Yamaoka; H Yabuuchi
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

4.  Long-term calcitonin therapy in postmenopausal osteoporosis.

Authors:  H E Gruber; J L Ivey; D J Baylink; M Matthews; W B Nelp; K Sisom; C H Chesnut
Journal:  Metabolism       Date:  1984-04       Impact factor: 8.694

5.  Reduced calcitonin reserve in young hypogonadic osteoporotic men.

Authors:  C Foresta; G Scanelli; G P Zanatta; B Busnardo; C Scandellari
Journal:  Horm Metab Res       Date:  1987-06       Impact factor: 2.936

6.  Osteoporosis in men with idiopathic hypogonadotropic hypogonadism.

Authors:  J S Finkelstein; A Klibanski; R M Neer; S L Greenspan; D I Rosenthal; W F Crowley
Journal:  Ann Intern Med       Date:  1987-03       Impact factor: 25.391
  6 in total
  3 in total

1.  Nasal human calcitonin for tumor-induced hypercalcemia.

Authors:  J C Dumon; A Magritte; J J Body
Journal:  Calcif Tissue Int       Date:  1992-07       Impact factor: 4.333

Review 2.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 3.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.